Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014593 | 0.83 | EPHX1 (0.48) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL15014614 | 0.83 | EPHX1 (0.48) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL14748218 | 0.81 | EPHX1 (0.47) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL556372 | 0.80 | EPHX1 (0.46) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL556878 | 0.80 | KMT2A (0.47) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL991949 | 0.79 | EPHX1 (0.52) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL14492250 | 0.79 | EPHX1 (0.52) | KMT2AEPHX1GAARAB9ANPC1 | |
| SCHEMBL15085653 | 0.79 | SMYD3 (0.56) | RAB9ASMYD3CYP3A4HPGDCYP2C19 | |
| SCHEMBL6876246 | 0.79 | SMYD3 (0.56) | RAB9ASMYD3CYP3A4HPGDCYP2C19 | |
| SCHEMBL14492252 | 0.76 | EPHX1 (0.53) | EPHX1GAARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1742001-A | Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands | ASTRAZENECA AB (SE) | 2006-03-01 | — | — | CN | disclosed |
| US-20050004130-A1 | New metabotropic glutamate receptor compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004130-A1 | New metabotropic glutamate receptor compounds | GRM1, GRIN1, GRM2 | KMT2A 2078/4885EPHX1 1179/4885GAA 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.